Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


26.08.2019

1 Am J Pathol
4 BJU Int
1 Br J Cancer
1 Cancer Res
1 Clin Cancer Res
1 Eur J Radiol
4 Eur Urol
1 Int J Oncol
2 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Nucl Med
1 J Surg Oncol
11 J Urol
1 JAMA
1 Nat Rev Urol
7 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Pathol

  1. RANI A, Dasgupta P, Murphy JJ
    Prostate Cancer- The Role of Inflammation and Chemokines.
    Am J Pathol. 2019 Aug 14. pii: S0002-9440(19)30663.
    PubMed     Text format     Abstract available


    BJU Int

  2. DESAI M, Bidair M, Bhojani N, Trainer A, et al
    WATER II (80-150 mL) procedural outcomes.
    BJU Int. 2019;123:106-112.
    PubMed     Text format     Abstract available

  3. WONG NC, Lam C, Patterson L, Shayegan B, et al
    Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.
    BJU Int. 2019;123:51-57.
    PubMed     Text format     Abstract available

  4. COOK GJR, Kulkarni M, Warbey VS
    PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer.
    BJU Int. 2019;124:357-358.
    PubMed     Text format    

  5. STONIER T, Simson N, Davis J, Challacombe B, et al
    Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) vs standard RARP: it's time for critical appraisal.
    BJU Int. 2019;123:5-7.
    PubMed     Text format    


    Br J Cancer

  6. EL-KENAWI A, Gatenbee C, Robertson-Tessi M, Bravo R, et al
    Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.
    Br J Cancer. 2019 Aug 16. pii: 10.1038/s41416-019-0542.
    PubMed     Text format     Abstract available


    Cancer Res

  7. KAWAMURA N, Nimura K, Saga K, Ishibashi A, et al
    SF3B2-mediated RNA splicing drives human prostate cancer progression.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-18-3965.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. LIU B, Li L, Yang G, Geng C, et al
    PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0317.
    PubMed     Text format     Abstract available


    Eur J Radiol

  9. DING K, Yao Y, Gao Y, Lu X, et al
    Diagnostic evaluation of diffusion kurtosis imaging for prostate cancer: Detection in a biopsy population.
    Eur J Radiol. 2019;118:138-146.
    PubMed     Text format     Abstract available


    Eur Urol

  10. VAN LEENDERS GJLH, Kweldam CF, Hollemans E, Kummerlin IP, et al
    Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    Eur Urol. 2019 Aug 19. pii: S0302-2838(19)30612.
    PubMed     Text format     Abstract available

  11. GLASER AW
    Resilience of men and the gap hypothesis of quality of life: Health utility outcome measurement in prostate cancer.
    Eur Urol. 2019 Aug 16. pii: S0302-2838(19)30607.
    PubMed     Text format    

  12. LU-YAO G, Nikita N, Keith SW, Nightingale G, et al
    Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
    Eur Urol. 2019 Aug 2. pii: S0302-2838(19)30585.
    PubMed     Text format     Abstract available

  13. DESAI NB, Courtney K, Subramaniam RM, Cadeddu JA, et al
    Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
    Eur Urol. 2019 Aug 14. pii: S0302-2838(19)30611.
    PubMed     Text format    


    Int J Oncol

  14. BOUAOUICHE S, Magadoux L, Dondaine L, Reveneau S, et al
    Glyceryl trinitrateinduced cytotoxicity of docetaxelresistant prostatic cancer cells is associated with differential regulation of clusterin.
    Int J Oncol. 2019;54:1446-1456.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  15. DEEK MP, Yu C, Phillips R, Song DY, et al
    Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641.
    PubMed     Text format     Abstract available

  16. BRUYNZEEL AME, Tetar SU, Oei SS, Senan S, et al
    A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33640.
    PubMed     Text format     Abstract available


    Int J Urol

  17. MURAKAMI Y, Satoh T, Tsumura H, Tabata KI, et al
    Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives.
    Int J Urol. 2019 Aug 22. doi: 10.1111/iju.14090.
    PubMed     Text format     Abstract available


    J Nucl Med

  18. DAVENPORT MS, Montgomery JS, Kunju LP, Siddiqui J, et al
    (18)F-choline PET/mpMRI for Detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies.
    J Nucl Med. 2019 Aug 16. pii: jnumed.119.225789. doi: 10.2967/jnumed.119.225789.
    PubMed     Text format     Abstract available


    J Surg Oncol

  19. JANSSEN SJ, Pereira NRP, Thio QCBS, Raskin KA, et al
    Physical function and pain intensity in patients with metastatic bone disease.
    J Surg Oncol. 2019;120:376-381.
    PubMed     Text format     Abstract available


    J Urol

  20. NAYAN M, Fleshner N, Bozzo A
    Editorial Comment.
    J Urol. 2019;202:504-505.
    PubMed     Text format    

  21. STOYANOVA R
    Editorial Comment.
    J Urol. 2019;202:505.
    PubMed     Text format    

  22. GORE JL
    Editorial Comment.
    J Urol. 2019;202:524.
    PubMed     Text format    

  23. KARAKIEWICZ PI
    Editorial Comment.
    J Urol. 2019;202:531.
    PubMed     Text format    

  24. O'NEILL M, Alibhai SMH
    Editorial Comment.
    J Urol. 2019;202:530-531.
    PubMed     Text format    

  25. PAK S, Park SY, Shin TJ, You D, et al
    Reply by Authors.
    J Urol. 2019;202:531-532.
    PubMed     Text format    

  26. MAGANTY A, Sabik LM, Sun Z, Eom KY, et al
    Undertreatment of Prostate Cancer in Rural Residents.
    J Urol. 2019 Aug 20:101097JU0000000000000500. doi: 10.1097/JU.0000000000000500.
    PubMed     Text format     Abstract available

  27. TOURINHO-BARBOSA RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, et al
    Focal Therapy for Localized Prostate Cancer with Either HIFU or Cryoablation: A Single Institution Experience.
    J Urol. 2019 Aug 22:101097JU0000000000000506. doi: 10.1097/JU.0000000000000506.
    PubMed     Text format     Abstract available

  28. DAMBAL S, Howard LE, Allott EH, Aronson WJ, et al
    Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration-Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494.
    PubMed     Text format     Abstract available

  29. ITO K, Yokomizo A, Tokunaga S, Arai G, et al
    Diagnostic Impacts of Clinical Laboratory-Based [-2] proPSA Indices on Any Grade, Gleason Grade Group >/=2 or >/=3 of Prostate Cancer in the PSA Below 10 ng/mL.
    J Urol. 2019 Aug 20:101097JU0000000000000495. doi: 10.1097/JU.0000000000000495.
    PubMed     Text format     Abstract available

  30. BAHLER CD, Green M, Hutchins GD, Cheng L, et al
    PSMA-Targeted Positron Emission Tomography (PET) in Evaluation of Patients with Primary Prostate Cancer: Comparison of Pre-operative [(68)Ga]Ga-PSMA-11 PET/CT, Immediate Post-operative Specimen [(68)Ga]Ga-PSMA-11 Imaging, and Whole Mount Pathology.
    J Urol. 2019 Aug 20:101097JU0000000000000501. doi: 10.1097/JU.0000000000000501.
    PubMed     Text format     Abstract available


    JAMA

  31. POLITE BN, Gluck AR, Brawley OW
    Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.
    JAMA. 2019;321:1663-1664.
    PubMed     Text format    


    Nat Rev Urol

  32. AL HUSSEIN AL AWAMLH B, Shoag JE
    Genomics and risk stratification in high-risk prostate cancer.
    Nat Rev Urol. 2019 Aug 21. pii: 10.1038/s41585-019-0227.
    PubMed     Text format    


    Prostate

  33. ROUSSEAU C, Le Thiec M, Ferrer L, Rusu D, et al
    Preliminary results of a (68) Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
    Prostate. 2019;79:1514-1522.
    PubMed     Text format     Abstract available


  34. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J, Rayford W. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004;60(2):141-152.
    Prostate. 2019;79:815.
    PubMed     Text format    

  35. MADUEKE I, Hu WY, Hu D, Swanson SM, et al
    The role of WNT10B in normal prostate gland development and prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23894.
    PubMed     Text format     Abstract available

  36. WU T, Zhao J, Liu Z, Shen P, et al
    Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23892.
    PubMed     Text format     Abstract available

  37. PATEL PG, Wessel T, Kawashima A, Okello JBA, et al
    A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23895.
    PubMed     Text format     Abstract available

  38. SARTOR O, Heinrich D, Mariados N, Mendez Vidal MJ, et al
    Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Prostate. 2019 Aug 23. doi: 10.1002/pros.23893.
    PubMed     Text format     Abstract available

  39. ZHAO C, Zhang W, Zhu X, Xu Y, et al
    TWIST2: A new candidate tumor suppressor in prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23889.
    PubMed     Text format     Abstract available


    Urology

  40. GHABILI K, Swallow M, Sherrer RL, Syed JS, et al
    Association between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4.
    Urology. 2019 Aug 13. pii: S0090-4295(19)30716.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: